Dasatinib inhibits DNA repair after radiotherapy specifically in pSFK-expressing tumor areas in head and neck xenograft tumors

Translational Oncology

Volumn 6, Issue 4, 2013, Pages 413-419

  Stegeman, Hanneke ^a   Span, Paul N ^a   Rijken, Paul F J W ^a   Cockx, Simone C ^a   Wheeler, Deric L ^b   Iida, Mari ^b   van der Kogel, Albert J ^a,b   Kaanders, Johannes H A M ^a   Bussink, Johan ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN TYROSINE KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA REPAIR; HEAD AND NECK TUMOR; HUMAN; HUMAN CELL; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR GROWTH; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84881048938     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13259     Document Type: Article

References (31)

1. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, and Milas L (2002). Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62, 7350-7356.
2. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al. (2006). Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354, 567-578.
3. Summy JM and Gallick GE (2003). Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev 22, 337-358.
4. Yeatman TJ (2004). A renaissance for SRC. Nat Rev Cancer 4, 470-480.
5. 1101 is associated with modulation of receptor function. J Biol Chem 274, 8335-8343.
6. Koppikar P, Choi SH, Egloff AM, Cai Q, Suzuki S, Freilino M, Nozawa H, Thomas SM, Gooding WE, Siegfried JM, et al. (2008). Combined inhibition of c-Src and epidermal growth factor receptor abrogates growth and invasion of head and neck squamous cell carcinoma. Clin Cancer Res 14, 4284-4291.
7. Zhang Q, Thomas SM, Xi S, Smithgall TE, Siegfried JM, Kamens J, Gooding WE, and Grandis JR (2004). SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 64, 6166-6173.
8. Wheeler DL, Iida M, Kruser TJ, Nechrebecki MM, Dunn EF, Armstrong EA, Huang S, and Harari PM (2009). Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab. Cancer Biol Ther 8, 696-703.
9. Li C, Iida M, Dunn EF, and Wheeler DL (2010). Dasatinib blocks cetuximab-and radiation-induced nuclear translocation of the epidermal growth factor receptor in head and neck squamous cell carcinoma. Radiother Oncol 97, 330-337.
10. Dittmann K, Mayer C, Fehrenbacher B, Schaller M, Raju U, Milas L, Chen DJ, Kehlbach R, and Rodemann HP (2005). Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280, 31182-31189.
11. Dittmann K, Mayer C, and Rodemann HP (2005). Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 76, 157-161.
12. Li C, Iida M, Dunn EF, Ghia AJ, and Wheeler DL (2009). Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 28, 3801-3813.
13. Montero JC, Seoane S, Ocana A, and Pandiella A (2011). Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res 17, 5546-5552.
14. Johnson FM, Saigal B, Talpaz M, and Donato NJ (2005). Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11, 6924-6932.
15. Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH, Frederick B, Rothschild BL, Raben D, Elvin P, et al. (2009). Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J Cancer Sci Ther 1, 52-61.
16. Sen B, Peng S, Woods DM, Wistuba I, Bell D, El-Naggar AK, Lai SY, and Johnson FM (2012). STAT5A-mediated SOCS2 expression regulates Jak2 and STAT3 activity following c-Src inhibition in head and neck squamous carcinoma. Clin Cancer Res 18, 127-139.
17. Brooks HD, Glisson BS, Bekele BN, Johnson FM, Ginsberg LE, El-Naggar A, Culotta KS, Takebe N, Wright J, Tran HT, et al. (2011). Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma. Cancer 117, 2112-2119.
18. Raju U, Riesterer O, Wang ZQ, Molkentine DP, Molkentine JM, Johnson FM, Glisson B, Milas L, and Ang KK (2012). Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways. Radiother Oncol 105, 241-249.
19. Stegeman H, Kaanders JH, Vander Kogel AJ, Iida M, Wheeler DL, Span PN, and Bussink J (2013). Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. Radiother Oncol 106, 383-389.
20. Bussink J, Kaanders JH, Rijken PF, Martindale CA, and Vander Kogel AJ (1998). Multiparameter analysis of vasculature, perfusion and proliferation in human tumour xenografts. Br J Cancer 77, 57-64.
21. Rijken PF, Bernsen HJ, Peters JP, Hodgkiss RJ, Raleigh JA, and Vander Kogel AJ (2000). Spatial relationship between hypoxia and the (perfused) vascular network in a human glioma xenograft: a quantitative multi-parameter analysis. Int J Radiat Oncol Biol Phys 48, 571-582.
22. Andersson T, Alfredsson L, Kallberg H, Zdravkovic S, and Ahlbom A (2005). Calculating measures of biological interaction. Eur J Epidemiol 20, 575-579.
23. Lin YC, Wu MH, Wei TT, Chung SH, Chen KF, Cheng AL, and Chen CC (2012). Degradation of epidermal growth factor receptor mediates dasatinib-induced apoptosis in head and neck squamous cell carcinoma cells. Neoplasia 14, 463-475.
24. Kim MJ, Byun JY, Yun CH, Park IC, Lee KH, and Lee SJ (2008). c-Src-p38 mitogen-activated protein kinase signaling is required for Akt activation in response to ionizing radiation. Mol Cancer Res 6, 1872-1880.
25. Stegeman H, Kaanders JH, Wheeler DL, Vander Kogel AJ, Verheijen MM, Waaijer SJ, Iida M, Grenman R, Span PN, and Bussink J (2012). Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck. BMC Cancer 12, 463.
26. Rodemann HP, Dittmann K, and Toulany M (2007). Radiation-induced EGFR-signaling and control of DNA-damage repair. IntJ Radiat Biol 83, 781-791.
27. O'Driscoll M and Jeggo PA (2006). The role of double-strand break repair- insights from human genetics. Nat Rev Genet 7, 45-54.
28. Chen RS, Jhan JY, Su YJ, Lee WT, Cheng CM, Ciou SC, Lin ST, Chuang SM, Ko JC, and Lin YW (2009). Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Exp Cell Res 315, 2658-2672.
29. Neal JA, Dang V, Douglas P, Wold MS, Lees-Miller SP, and Meek K (2011). Inhibition of homologous recombination by DNA-dependent protein kinase requires kinase activity, is titratable, and is modulated by autophosphorylation. Mol Cell Biol 31, 1719-1733.
30. Mahbub Hasan AK, Ijiri T, and Sato K (2012). Involvement of Src in the adaptation of cancer cells under microenvironmental stresses. J Signal Transduct 2012, 483-796.
31. Pham NA, Magalhaes JM, Do T, Schwock J, Dhani N, Cao PJ, Hill RP, and Hedley DW (2009). Activation of Src and Src-associated signaling pathways in relation to hypoxia in human cancer xenograft models. Int J Cancer 124, 280-286.